Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV Treatment
Monoclonal antibody among HIV therapies discussed at human virology meeting
December 12th, 2004
Tanox, Inc. (TNOX) medical director Stanley Lewis recently presented findings from the phase 1 clinical trial of TNX-355 for the treatment of human immunodeficiency virus (HIV) at the 2004 International Meeting of the Institute of Human Virology (IHV) in Baltimore, Maryland. In a conference track titled "New Approaches to HIV Therapy," Lewis discussed the safety and anti-HIV activity of TNX-355 in testing conducted in HIV-infected patients during the trial. TNX-355 is a humanized, non-immunosuppressive anti-CD4 monoclonal antibody that works by blocking the ability of HIV to enter CD4 cells. It is one of a new class of drugs called viral entry...
Source: Medical Letter on the CDC & FDA (2004-12-12)
|
